Benzinga | Mar 1, 2021 06:11AM EST

ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis

74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90

- Data supportive of ASLAN004's potential as a novel, first-in-class antibody targeting IL-13R with differentiated efficacy and safety profile in atopic dermatitis

- Management to host conference call and webcast today, 1 March, at 8am ET / 9pm SGT